Literature DB >> 11283134

S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.

P Malmström1, P O Bendahl, P Boiesen, N Brünner, I Idvall, M Fernö.   

Abstract

PURPOSE: Histologic grade, Nottingham Prognostic Index (NPI), estrogen receptor (ER) and progesterone receptor (PgR) status, and tumor size have previously been shown to be important prognostic indicators for distant recurrence of breast cancer. The purpose of this study was to compare the prognostic value of these factors with flow cytometric S-phase fraction (SPF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor type 1 (PAI-1) in premenopausal patients with lymph node-negative breast cancer. PATIENTS AND METHODS: In 237 consecutive premenopausal patients with lymph node-negative breast cancer and freshly frozen tumor material available, SPF, ER and PgR status, uPA and its inhibitor PAI-1, histologic grade, and NPI were evaluated.
RESULTS: SPF was univariately the most powerful prognostic factor for distant recurrence, followed by uPA, histologic grade, PgR, age, ER, NPI, and PAI-1, the latter being nonsignificant. Multivariate analysis revealed that neither NPI nor histologic grade was significant after adjustment for SPF, a fact that may be explained by the strong association between these factors. uPA was, however, an independent prognostic factor in addition to SPF, NPI, or histologic grade.
CONCLUSION: In this prospective study, SPF and uPA were found to be independent prognostic factors in premenopausal women with lymph node-negative breast cancer. We suggest that SPF, if performed under standardized conditions, can replace histologic grade as a selection instrument for adjuvant medical treatment. The value of the combination of SPF and uPA needs to be confirmed in an independent prospective trial.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283134     DOI: 10.1200/JCO.2001.19.7.2010

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

1.  Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.

Authors:  Karolina Holm; Dorthe Grabau; Kristina Lövgren; Steina Aradottir; Sofia Gruvberger-Saal; Jillian Howlin; Lao H Saal; Stephen P Ethier; Pär-Ola Bendahl; Olle Stål; Per Malmström; Mårten Fernö; Lisa Rydén; Cecilia Hegardt; Åke Borg; Markus Ringnér
Journal:  Mol Oncol       Date:  2012-06-20       Impact factor: 6.603

2.  Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Authors:  Siker Kimbung; Anikó Kovács; Pär-Ola Bendahl; Per Malmström; Mårten Fernö; Thomas Hatschek; Ingrid Hedenfalk
Journal:  Mol Oncol       Date:  2013-10-14       Impact factor: 6.603

3.  Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients.

Authors:  Praveen Ravishankaran; R Karunanithi
Journal:  World J Surg Oncol       Date:  2011-02-06       Impact factor: 2.754

Review 4.  uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.

Authors:  Michael J Duffy; Patricia M McGowan; Nadia Harbeck; Christoph Thomssen; Manfred Schmitt
Journal:  Breast Cancer Res       Date:  2014-08-22       Impact factor: 6.466

5.  Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.

Authors:  Kristina E Aaltonen; Ann H Rosendahl; Hans Olsson; Per Malmström; Linda Hartman; Mårten Fernö
Journal:  BMC Cancer       Date:  2014-11-03       Impact factor: 4.430

6.  CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.

Authors:  H Jernström; E Bågeman; C Rose; P-E Jönsson; C Ingvar
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

7.  Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-associated hypercoagulation.

Authors:  Colin E Evans; Pär-Ola Bendahl; Mattias Belting; Cristina Branco; Randall S Johnson
Journal:  Blood       Date:  2015-12-23       Impact factor: 22.113

8.  Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?

Authors:  P Chollet; S Amat; E Belembaogo; H Curé; M de Latour; J Dauplat; G Le Bouëdec; M-A Mouret-Reynier; J-P Ferrière; F Penault-Llorca
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

9.  Protease Activated Receptors 1 and 2 Correlate Differently with Breast Cancer Aggressiveness Depending on Tumor ER Status.

Authors:  Jon Lidfeldt; Pär-Ola Bendahl; Carina Forsare; Per Malmström; Mårten Fernö; Mattias Belting
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

10.  The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.

Authors:  Marie Klintman; Carina Strand; Cecilia Ahlin; Sanda Beglerbegovic; Marie-Louise Fjällskog; Dorthe Grabau; Einar Gudlaugsson; Emiel A M Janssen; Kristina Lövgren; Ivar Skaland; Pär-Ola Bendahl; Per Malmström; Jan P A Baak; Mårten Fernö
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.